Schlieren, Switzerland

Clara Metz

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Molecular Partners Ag. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Clara Metz: Innovator in Recombinant Binding Proteins

Introduction

Clara Metz is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant binding proteins.

Latest Patents

Clara Metz holds a patent for "Recombinant binding proteins targeting HER2 and serum albumin, and their uses." This patent discloses new recombinant binding proteins that comprise designed ankyrin repeat domains with binding specificity for HER2 and serum albumin. The patent also includes nucleic acids encoding these recombinant binding proteins, pharmaceutical compositions that contain them, and their applications in treating various diseases.

Career Highlights

Clara Metz is associated with Molecular Partners AG, a company known for its innovative approaches in the field of biopharmaceuticals. Her work focuses on the design and application of binding proteins that can target specific proteins involved in disease processes.

Collaborations

Clara has collaborated with notable colleagues, including Ulrike Fiedler and Ignacio Dolado, to advance her research and development efforts in the field.

Conclusion

Clara Metz is a key figure in the biotechnology sector, with her innovative work on recombinant binding proteins paving the way for new therapeutic options. Her contributions continue to impact the treatment of diseases, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…